Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Overview

This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model which can predict neoadjuvant endocrine therapeutic results.

Full Title of Study: “Neoadjuvant Tucidinostat and Exemestane in Estrogen Receptor-Positive Early Breast Cancer (NeoTEE)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 1, 2023

Detailed Description

This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients.This study will recruit 30 patients. The 30 patients will receive 25 mg exemestane QD for 26 weeks. Tucidinostat will be prescribed 30 mg BIW from week 3 to week 26. During neoadjuvant treatment biopsy, CEUS and MRI will be perfomed according to protocol to evaluate the therapeutic results. Genetic testing will also be performed before and after neoadjuvant treatment to explore the predictive value. MRI evaluated ORR is primary end point. CEUS evaluated ORR, pCR, AE and RCB are secondary end point.

Interventions

  • Drug: Tucidinostat
    • Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26
  • Drug: Exemestane
    • Exemestane: 25 mg QD from week 1 to week 26.
  • Drug: Ovarian function suppression
    • If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.

Arms, Groups and Cohorts

  • Experimental: Tucidinostat and Exemestane
    • Patients receive exemestane from week 1 to week 26 and Tucidinostat BIW from week 3 to week 26. Courses continue in the absence of disease progression or unacceptable toxicity. If the patient is premenopausal, leuprorelin or goserelin will be prescribed.

Clinical Trial Outcome Measures

Primary Measures

  • objective response rate (ORR) evaluated by MRI
    • Time Frame: Up to 31 weeks
    • ORR is defined as percentage of participants with Complete Response and Partial Response, assessed by the investigators using MRI according to the Response Evaluation Criteria in Solid Tumors (RECIST)

Secondary Measures

  • objective response rate (ORR) evaluated by CEUS
    • Time Frame: Up to 31 weeks
    • Contrast-enhanced ultrasound will also be performed to assess ORR
  • pathologic complete response rate (pCR)
    • Time Frame: Up to 31 weeks
    • The percentage of participants with pathologically assessed ypT0 and ypTis of breast disease.
  • Adverse effect (AE)
    • Time Frame: Up to 31 weeks
    • All advese effect events related with Tucidinostat and Exemestane.
  • Residual Cancer Burden (RCB)
    • Time Frame: Up to 31 weeks
    • Pathologilly assessed residual cancer burden according to MD Anderson protocol.

Participating in This Clinical Trial

Inclusion Criteria

1. Written informed consent must be signed; 2. Eastern Cooperative Oncology Group Performance Status: 0~1; 3. Histological confirmation of estrogen receptor (ER) positive and HER 2 negative invasive breast cancer; 4. Age ≥18 years old; 5. No distant metastatic disease; 6. The disease condition is stage II or stage III; 7. Laboratory exam criteria for enrollment: HGB≥10g/dl, WBC≥4,000/mm3, PLT≥100,000/mm3, GOT, GPT, ALP≤2 times ULN, TBIL, CCr≤1.5 times ULN. Exclusion Criteria:

1. Patients who are pregnant or lactating at the time of randomization or refuse to contraception. 2. Patients who received organ transplantation (include bone marrow autologous transplantation and stem cell transplantation). 3. Patients who have other malignant diseases within 5 years, except for cured skin basal cell carcinoma, flat cell carcinoma or cervical carcinoma in situ 4. Patients with psychiatric disorder, peripheral or central nerve system disease or any disorder, which compromises ability to give informed consent or participate in this study. 5. Patients with sever hepatic, renal,cardiovascular, respiratory, digestive diseases or uncontrolled diabetes. 6. Patients who had myocardial infarction in the past 12 months. 7. Patients who participate in other clinical trail. 8. Patients who allergy to goserelin, leuprorelin, tucidinostat or aromatase inhibitor.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • First Affiliated Hospital, Sun Yat-Sen University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ying Lin, Vice Director of Department of Breast Surgery – First Affiliated Hospital, Sun Yat-Sen University
  • Overall Official(s)
    • Ying Lin, MD, Principal Investigator, First Affiliated Hospital, Sun Yat-Sen University

References

Jiang Z, Li W, Hu X, Zhang Q, Sun T, Cui S, Wang S, Ouyang Q, Yin Y, Geng C, Tong Z, Cheng Y, Pan Y, Sun Y, Wang H, Ouyang T, Gu K, Feng J, Wang X, Wang S, Liu T, Gao J, Cristofanilli M, Ning Z, Lu X. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):806-815. doi: 10.1016/S1470-2045(19)30164-0. Epub 2019 Apr 27.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.